Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Botensilimab by Agenus for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Botensilimab by Agenus for Esophageal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
Botensilimab by Agenus for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
Botensilimab by Agenus for Leiomyosarcoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs...
Botensilimab by Agenus for Angiosarcoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Angiosarcoma. According to GlobalData, Phase I drugs...
Botensilimab by Agenus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Botensilimab by Agenus for Renal Cell Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...
Botensilimab by Agenus for Endometrial Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Metastatic Pancreatic Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Hepatocellular Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...
Botensilimab by Agenus for Cervical Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Solid Tumor: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Non-Small Cell Lung Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...